Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.
Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.
First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.
A simple blood test can identify post-chemo patients with the NPM1 gene mutation.
Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.
A new study examined levels of procedure-related anxiety in children with standard-risk acute lymphoblastic leukemia (ALL).
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and MetastasisJanuary 11, 2016
Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.
Adolescents and young adults (AYAs) with hematologic malignancies experience significant psychological morbidities during treatment and early survivorship.
People residing at higher latitudes, who are exposed to lower levels of sunlight/ultraviolet B light and have a higher prevalence of vitamin D deficiency, are at least twice as likely to develop leukemia than equatorial populations.
Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood CancersJanuary 04, 2016
In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.
A team of researchers discovered a method for early detection of aspergillosis, a potentially deadly fungal infection, in patients whose disease or treatment involves immune system suppression.
A new analysis indicates that certain characteristics may indicate a higher risk of developing leukemia after chemotherapy and/or radiation for breast cancer survivors.
Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene VariationsDecember 22, 2015
Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).
Improvements were observed in progression-free survival, overall survival, and response rate for ibrutinib usage.
Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLLDecember 10, 2015
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
Arsenic trioxide can lower relapse rates in first-line treatment of standard risk acute promyelocytic leukemia (APL), but proper administration is required.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.
Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid LeukemiaDecember 06, 2015
The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.
Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).
Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.
Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.
A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.
- Understanding Drug Naming Nomenclature
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer
- Proposed Regimen for Ovarian Cancer Is Aggressive, But Could Achieve a 50% Cure Rate
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Common Painkiller Has Anticancer Effects
- Palliative Care is Cost Effective for Cancer Patients, and Increases With Comorbidities
- Understanding Participation Factors Related to Web- and Phone-based Tobacco Cessation Programs
- Satisfaction With Navigators Associated With Satisfaction With Cancer-related Care
- Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis
- Novel Procedures Improves Staging of Lymph Nodes in Patients With Breast Cancer
- Risk of Metabolic Syndrome Increased in Survivors of Childhood Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|